Cargando…

Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology

With the rapid growth of molecular biology, in vivo imaging of such molecular process (i.e., molecular imaging) has been well developed. The molecular imaging has been focused on justifying advanced treatments and for assessing the treatment effects. Most of molecular imaging has been developed usin...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamaki, Nagara, Yoshinaga, Keiichiro
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032201/
https://www.ncbi.nlm.nih.gov/pubmed/21082300
http://dx.doi.org/10.1007/s12350-010-9305-4
_version_ 1782197427881639936
author Tamaki, Nagara
Yoshinaga, Keiichiro
author_facet Tamaki, Nagara
Yoshinaga, Keiichiro
author_sort Tamaki, Nagara
collection PubMed
description With the rapid growth of molecular biology, in vivo imaging of such molecular process (i.e., molecular imaging) has been well developed. The molecular imaging has been focused on justifying advanced treatments and for assessing the treatment effects. Most of molecular imaging has been developed using PET camera and suitable PET radiopharmaceuticals. However, this technique cannot be widely available and we need alternative approach. (123)I-labeled compounds have been also suitable for molecular imaging using single-photon computed tomography (SPECT) (123)I-labeled meta-iodobenzylguanidine (MIBG) has been used for assessing severity of heart failure and prognosis. In addition, it has a potential role to predict fatal arrhythmia, particularly for those who had and are planned to receive implantable cardioverter-defibrillator treatment. (123)I-beta-methyl-iodophenylpentadecanoic acid (BMIPP) plays an important role for identifying ischemia at rest, based on the unique capability to represent persistent metabolic alteration after recovery of ischemia, so called ischemic memory. Since BMIPP abnormalities may represent severe ischemia or jeopardized myocardium, it may permit risk analysis in CAD patients, particularly for those with chronic kidney disease and/or hemodialysis patients. This review will discuss about recent development of these important iodinated compounds.
format Text
id pubmed-3032201
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-30322012011-03-16 Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology Tamaki, Nagara Yoshinaga, Keiichiro J Nucl Cardiol Review Article With the rapid growth of molecular biology, in vivo imaging of such molecular process (i.e., molecular imaging) has been well developed. The molecular imaging has been focused on justifying advanced treatments and for assessing the treatment effects. Most of molecular imaging has been developed using PET camera and suitable PET radiopharmaceuticals. However, this technique cannot be widely available and we need alternative approach. (123)I-labeled compounds have been also suitable for molecular imaging using single-photon computed tomography (SPECT) (123)I-labeled meta-iodobenzylguanidine (MIBG) has been used for assessing severity of heart failure and prognosis. In addition, it has a potential role to predict fatal arrhythmia, particularly for those who had and are planned to receive implantable cardioverter-defibrillator treatment. (123)I-beta-methyl-iodophenylpentadecanoic acid (BMIPP) plays an important role for identifying ischemia at rest, based on the unique capability to represent persistent metabolic alteration after recovery of ischemia, so called ischemic memory. Since BMIPP abnormalities may represent severe ischemia or jeopardized myocardium, it may permit risk analysis in CAD patients, particularly for those with chronic kidney disease and/or hemodialysis patients. This review will discuss about recent development of these important iodinated compounds. Springer-Verlag 2010-11-17 2011 /pmc/articles/PMC3032201/ /pubmed/21082300 http://dx.doi.org/10.1007/s12350-010-9305-4 Text en © The Author(s) 2010 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Review Article
Tamaki, Nagara
Yoshinaga, Keiichiro
Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology
title Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology
title_full Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology
title_fullStr Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology
title_full_unstemmed Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology
title_short Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology
title_sort novel iodinated tracers, mibg and bmipp, for nuclear cardiology
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032201/
https://www.ncbi.nlm.nih.gov/pubmed/21082300
http://dx.doi.org/10.1007/s12350-010-9305-4
work_keys_str_mv AT tamakinagara noveliodinatedtracersmibgandbmippfornuclearcardiology
AT yoshinagakeiichiro noveliodinatedtracersmibgandbmippfornuclearcardiology